ClinicalTrials.gg
CompletedNCT03122769Updated Apr 20, 2018

Cardiac Uptake of Metformin, Visualized by Positron Emission Tomography

A Phase 1 interventional study of 11C-metformin in Heart Failure, Systolic, sponsored by Henrik Wiggers. Completed at 1 site in Denmark. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2018-04-20.

Sponsored by Henrik Wiggers · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Heart Failure, Systolic with a site in Denmark — 3 open to participants now, 6 under way, none of them phase 3. Heart Failure, Systolic · Denmark.

Enrollment
10th of 11
6 · median 44
Started
2017
with 2 others
Phase 1
Only one
of the 15
Registered
5th of 15
by date
Lead sponsor
2 of 15
Henrik Wiggers

Among the 15 studies in Heart Failure, Systolic with a site in Denmark, this one is the 10th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2017, is the only one in phase 1, and was the 5th registered.

Heart Failure, Systolic

230 studies on the registry are indexed under Heart Failure, Systolic; 50 are open to participants now.

Browse Heart Failure, Systolic studies →

Open to participants now

3 of the 15 studies in Heart Failure, Systolic with a site in Denmark are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 28 Heart Failure, Systolic studies recruiting now, 18 (64%) set no upper age limit and 2 (7%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Heart Failure, Systolic with a site in Denmark, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate if metformin is taken up into the failing myocardium. Recent experimental and epidemiological studies have shown beneficial effects of metformin on heart failure. It is unknown whether this effect is direct or indirect.

The aim of the study is to investigate if metformin is taken up in heart failure using a novel 11C-metformin tracer and positron emission tomography (PET).

03

Conditions studied

  • Heart Failure, Systolic

Keywords

  • Metformin
  • Heart Failure
  • Organic cation transporter
  • Pharmacogenetics
  • Pharmacokinetics
  • Positron Emission Tomography
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with chronic heart failure, \<45%
  • (NYHA) class I, II, III
  • Relatively preserved renal function ( > 30 ml/min)
  • Ability to understand the written patient information and to give
  • Negative p-HCG for women of

Exclusion criteria

Exclusion Criteria:

  • Known allergy to metformin
  • Age \< 18 years
  • Current abuse of alcohol or drugs
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    11C-metformin

    All participants allocated to the study will be included in this arm

    Radiation: 11C-metformin

Interventions

  • Radiation11C-metformin

    200 MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Positron Emission Tomography

06

What researchers measure

Primary outcomes

  1. Metformin uptake in the failing myocardium

    Cardiac uptake is evaluated through analysis of acquired PET-images.

    Time frame: 12 months

07

Study locations

1 site
  • Aarhus University Hospital, Department of Cardiology, Palle Juul-Jensens Boulevard 99
    Aarhus N, 8200, Denmark
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Apr 2018, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2017
First posted
Apr 21, 2017
StartActual
Dec 1, 2017
Primary completionActual
Apr 10, 2018
CompletionActual
Apr 10, 2018
Last update
Apr 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03122769
Lead sponsor
Henrik Wiggers
Responsible party
Henrik Wiggers (Senior consultant, associate professor, MD, PhD, DMSc, Aarhus University Hospital) — Sponsor-investigator
First posted
Apr 21, 2017
Start date
Dec 1, 2017
Primary completion
Apr 10, 2018
Completion
Apr 10, 2018
Last update
Apr 20, 2018

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion